PREDICT - Prospective Observational Study Of A Cohort Of Naive Patients With Chronic Hepatitis C Infected With HCV Genotype 1 Low Viral Load (HCV LVL 1) And Treated With Peg-Intron [peginterferon alfa 2b] 1.5 ug/Kg/Week Plus Rebetol [ribavirin] 800-1200 mg/Day Who Achieved A Negative HCV-RNA At Week 4 and at Week 24.

Trial Profile

PREDICT - Prospective Observational Study Of A Cohort Of Naive Patients With Chronic Hepatitis C Infected With HCV Genotype 1 Low Viral Load (HCV LVL 1) And Treated With Peg-Intron [peginterferon alfa 2b] 1.5 ug/Kg/Week Plus Rebetol [ribavirin] 800-1200 mg/Day Who Achieved A Negative HCV-RNA At Week 4 and at Week 24.

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Apr 2014

At a glance

  • Drugs Peginterferon alfa-2b (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms PREDICT
  • Sponsors Merck & Co; Merck Sharp & Dohme; Schering-Plough
  • Most Recent Events

    • 12 Jan 2011 Planned End Date changed from 1 Nov 2010 to 1 Jun 2011 as reported by ClinicalTrials.gov [NCT01054742].
    • 12 Jan 2011 Planned End Date changed from 1 Nov 2010 to 1 Jun 2011 as reported by ClinicalTrials.gov [NCT01054742].
    • 12 Jan 2011 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov [NCT01054742].
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top